We are live on ! Find out more
CABA icon

Cabaletta Bio

95 hedge funds and large institutions have $167M invested in Cabaletta Bio in 2025 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 33 increasing their positions, 18 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,725% more call options, than puts

Call options by funds: $5.09M | Put options by funds: $279K

275% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 8

83% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 18

27% more funds holding

Funds holding: 7595 (+20)

3.53% more ownership

Funds ownership: 75.67%79.2% (+3.5%)

3% more capital invested

Capital invested by funds: $162M → $167M (+$4.96M)

Holders
95
Holders Change
+20
Holders Change %
+26.67%
% of All Funds
1.15%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
30
Increased
33
Reduced
18
Closed
8
Calls
$5.09M
Puts
$279K
Net Calls
+$4.81M
Net Calls Change
-$353K
Name Holding Trade Value Shares
Change
Change in
Stake
T. Rowe Price Investment Management
1
T. Rowe Price Investment Management
Maryland
$21.6M +$3.71M +1,495,768 +18%
BCLSI
2
Bain Capital Life Sciences Investors
Massachusetts
$21.2M
Jennison Associates
3
Jennison Associates
New York
$19.5M +$1.01M +408,162 +5%
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$19.3M
Vanguard Group
5
Vanguard Group
Pennsylvania
$9.68M +$567K +228,699 +5%
CAM
6
Cormorant Asset Management
Massachusetts
$9.64M -$1.49M -600,000 -12%
Millennium Management
7
Millennium Management
New York
$5.99M +$5.08M +2,050,099 +298%
BlackRock
8
BlackRock
New York
$5.1M +$1.75M +707,598 +44%
SCM
9
Superstring Capital Management
New York
$4.94M +$1.76M +709,025 +46%
Two Sigma Investments
10
Two Sigma Investments
New York
$4.03M +$3.39M +1,369,324 +291%
Renaissance Technologies
11
Renaissance Technologies
New York
$3.33M +$454K +183,160 +14%
Morgan Stanley
12
Morgan Stanley
New York
$2.94M -$325K -130,968 -9%
WP
13
Woodline Partners
California
$2.74M -$2.19M -885,106 -41%
SSA
14
Schonfeld Strategic Advisors
New York
$2.64M +$396K +159,901 +15%
T. Rowe Price Associates
15
T. Rowe Price Associates
Maryland
$2.4M -$498K -200,990 -16%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$2.38M +$410K +165,476 +18%
Marshall Wace
17
Marshall Wace
United Kingdom
$2.1M -$909K -366,967 -28%
OM
18
Opaleye Management
Massachusetts
$1.97M +$226K +91,118 +11%
IC
19
Ikarian Capital
Texas
$1.97M +$2.23M +900,000 New
Schroder Investment Management Group
20
Schroder Investment Management Group
United Kingdom
$1.63M +$1.88M +756,637 New
Two Sigma Advisers
21
Two Sigma Advisers
New York
$1.62M +$1.01M +406,900 +123%
BGM
22
Burkehill Global Management
New York
$1.53M
Jane Street
23
Jane Street
New York
$1.45M +$1.38M +557,487 +533%
Ensign Peak Advisors
24
Ensign Peak Advisors
Utah
$1.2M +$1.36M +550,000 New
KCA
25
KVP Capital Advisors
California
$1.11M +$1.25M +505,431 New

CABA Hedge Fund Activity: Q4 2025 in Review

95 of the 8,245 institutional investors tracked by Wall St. Rank reported a position in Cabaletta Bio (CABA) for Q4 2025, worth a combined $167M — up 3.1% from $162M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new CABA positions and 8 closed out — a net gain of 22 holders — while 33 added to existing stakes and 18 trimmed.

The largest buyer was Millennium Management, adding an estimated $5.08M. The largest seller was Heights Capital Management, exiting entirely with an estimated $4.88M sold.

  • 95 institutional investors held Cabaletta Bio (CABA) as of Q4 2025, up from 75 in Q3 2025.
  • Funds reported $167M of Cabaletta Bio stock for Q4 2025, up 3.1% quarter-over-quarter.
  • 30 funds opened new Cabaletta Bio positions in Q4 2025 and 8 closed out, a net change of +22 holders.
  • The largest Cabaletta Bio buyer in Q4 2025 was Millennium Management, an estimated $5.08M added.
  • The largest Cabaletta Bio seller in Q4 2025 was Heights Capital Management, an estimated $4.88M sold.

Based on aggregated 13F filings for Q4 2025.